Sort   by:  
 Page size 
UnknownTivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
Not available
S-EPMC5569677 | biostudies-literature
UnknownRandomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
Not available
S-EPMC6018511 | biostudies-literature
UnknownCOMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma.
Not available
S-EPMC7518515 | biostudies-literature
UnknownCabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
Not available
S-EPMC8521736 | biostudies-literature
UnknownPhase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.
Not available
S-EPMC3394097 | biostudies-literature
UnknownOnce-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.
Not available
S-EPMC3394099 | biostudies-literature
UnknownIL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.
Not available
S-EPMC4385958 | biostudies-literature
UnknownModeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
Not available
S-EPMC7552889 | biostudies-literature
UnknownNew prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.
Not available
S-EPMC9835946 | biostudies-literature
UnknownAvelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.
Not available
S-EPMC10306435 | biostudies-literature
Sort   by:  
 Page size